These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 37151596)

  • 41. Gaps in Evidence-based Treatment of Concurrent Attention Deficit Hyperactivity Disorder and Opioid Use Disorder: A Scoping Review.
    Ramey OL; Bonny AE; Silva Almodóvar A; Nahata MC
    Ann Pharmacother; 2023 Aug; 57(8):978-990. PubMed ID: 36510631
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A qualitative analysis of barriers to opioid agonist treatment for racial/ethnic minoritized populations.
    Husain JM; Cromartie D; Fitzelle-Jones E; Brochier A; Borba CPC; Montalvo C
    J Subst Abuse Treat; 2023 Jan; 144():108918. PubMed ID: 36403456
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Patient Barriers and Facilitators to Medications for Opioid Use Disorder in Primary Care.
    Tofighi B; Williams AR; Chemi C; Suhail-Sindhu S; Dickson V; Lee JD
    Subst Use Misuse; 2019; 54(14):2409-2419. PubMed ID: 31429351
    [No Abstract]   [Full Text] [Related]  

  • 44. Concerns among people who use opioids during the COVID-19 pandemic: a natural language processing analysis of social media posts.
    Sarker A; Nataraj N; Siu W; Li S; Jones CM; Sumner SA
    Subst Abuse Treat Prev Policy; 2022 Mar; 17(1):16. PubMed ID: 35248103
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Developing an opioid use disorder treatment cascade: A review of quality measures.
    Williams AR; Nunes EV; Bisaga A; Pincus HA; Johnson KA; Campbell AN; Remien RH; Crystal S; Friedmann PD; Levin FR; Olfson M
    J Subst Abuse Treat; 2018 Aug; 91():57-68. PubMed ID: 29910015
    [TBL] [Abstract][Full Text] [Related]  

  • 46. An examination between treatment type and treatment retention in persons with opioid and co-occurring alcohol use disorders.
    Mintz CM; Presnall NJ; Xu KY; Hartz SM; Sahrmann JM; Bierut LJ; Grucza RA
    Drug Alcohol Depend; 2021 Sep; 226():108886. PubMed ID: 34245997
    [TBL] [Abstract][Full Text] [Related]  

  • 47. "Will My Baby Be OK?" A Qualitative Analysis of Pregnant Women's Suboxone
    Moore DJ; Butzlaff A
    J Am Psychiatr Nurses Assoc; 2023; 29(3):185-193. PubMed ID: 37038973
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Comparative Effectiveness of Different Treatment Pathways for Opioid Use Disorder.
    Wakeman SE; Larochelle MR; Ameli O; Chaisson CE; McPheeters JT; Crown WH; Azocar F; Sanghavi DM
    JAMA Netw Open; 2020 Feb; 3(2):e1920622. PubMed ID: 32022884
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Age related medication for addiction treatment (MAT) use for opioid use disorder among Medicaid-insured patients in New York.
    Neighbors CJ; Choi S; Healy S; Yerneni R; Sun T; Shapoval L
    Subst Abuse Treat Prev Policy; 2019 Jun; 14(1):28. PubMed ID: 31238952
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Managing Acute Pain in Patients Taking Medication for Opioid Use Disorder: a Rapid Review.
    Veazie S; Mackey K; Peterson K; Bourne D
    J Gen Intern Med; 2020 Dec; 35(Suppl 3):945-953. PubMed ID: 33145688
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A systematic review of patients' and providers' perspectives of medications for treatment of opioid use disorder.
    Cioe K; Biondi BE; Easly R; Simard A; Zheng X; Springer SA
    J Subst Abuse Treat; 2020 Dec; 119():108146. PubMed ID: 33138929
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Impact of prenatal substance use policies on commercially insured pregnant females with opioid use disorder.
    Tabatabaeepour N; Morgan JR; Jalali A; Kapadia SN; Meinhofer A
    J Subst Abuse Treat; 2022 Sep; 140():108800. PubMed ID: 35577664
    [TBL] [Abstract][Full Text] [Related]  

  • 53. METHADONE INITIATION IN THE EMERGENCY DEPARTMENT FOR OPIOID USE DISORDER: A CASE SERIES.
    Huo S; Heil J; Salzman MS; Carroll G; Haroz R
    J Emerg Med; 2023 Mar; 64(3):391-396. PubMed ID: 37019500
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A qualitative study comparing physician-reported barriers to treating addiction using buprenorphine and extended-release naltrexone in U.S. office-based practices.
    Andraka-Christou B; Capone MJ
    Int J Drug Policy; 2018 Apr; 54():9-17. PubMed ID: 29324253
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Open-label dose-extending placebos for opioid use disorder: a protocol for a randomised controlled clinical trial with methadone treatment.
    Belcher AM; Cole TO; Greenblatt AD; Hoag SW; Epstein DH; Wagner M; Billing AS; Massey E; Hamilton KR; Kozak ZK; Welsh CJ; Weintraub E; Wickwire EM; Wish ED; Kaptchuk TJ; Colloca L
    BMJ Open; 2019 Jun; 9(6):e026604. PubMed ID: 31230007
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Use of Medications for Treatment of Opioid Use Disorder Among US Medicaid Enrollees in 11 States, 2014-2018.
    ; Donohue JM; Jarlenski MP; Kim JY; Tang L; Ahrens K; Allen L; Austin A; Barnes AJ; Burns M; Chang CH; Clark S; Cole E; Crane D; Cunningham P; Idala D; Junker S; Lanier P; Mauk R; McDuffie MJ; Mohamoud S; Pauly N; Sheets L; Talbert J; Zivin K; Gordon AJ; Kennedy S
    JAMA; 2021 Jul; 326(2):154-164. PubMed ID: 34255008
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Initiation and Treatment Discontinuation of Medications for Opioid Use Disorder in Pregnant People Compared With Nonpregnant People.
    Xu KY; Jones HE; Schiff DM; Martin CE; Kelly JC; Carter EB; Bierut LJ; Grucza RA
    Obstet Gynecol; 2023 Apr; 141(4):845-853. PubMed ID: 36897142
    [TBL] [Abstract][Full Text] [Related]  

  • 58. "In their mind, they always felt less than": The role of peers in shifting stigma as a barrier to opioid use disorder treatment retention.
    Anvari MS; Kleinman MB; Massey EC; Bradley VD; Felton JW; Belcher AM; Magidson JF
    J Subst Abuse Treat; 2022 Jul; 138():108721. PubMed ID: 35067397
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Opioid use disorder in Germany: healthcare costs of patients in opioid maintenance treatment.
    Reimer J; Vogelmann T; Trümper D; Scherbaum N
    Subst Abuse Treat Prev Policy; 2019 Dec; 14(1):57. PubMed ID: 31842942
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Neurocognitive, psychiatric, and substance use characteristics in a diverse sample of persons with OUD who are starting methadone or buprenorphine/naloxone in opioid treatment programs.
    Scott TM; Arnsten J; Olsen JP; Arias F; Cunningham CO; Rivera Mindt M
    Addict Sci Clin Pract; 2021 Oct; 16(1):64. PubMed ID: 34689841
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.